Epidemiological analysis of HPV in Sichuan during 2014-2021.

INTRODUCTION Cervical cancer is a common malignancy among woman, strong molecular epidemiological data show that high risk HPV infection is the main cause of cervical cancer. MATERIAL AND METHODS Samples were collected from Sichuan women's and children's hospital based on the relevant guidelines and regulations, HPV DNA was extracted and evaluated by Human Papillomavirus Genotyping Kit for 21 types, according to the manufacturer's guidelines to analyze the epidemic age, mixed infection types, variation trend of HPV types in Sichuan from 2014 to 2021; Results: Out of 51174 samples11165 (21.82 %) HPV positive samples were detected, all belonging to alpha family, 53.32 % HPV positive samples and 61.51 % high-risk (HR) HPV positive samples are alpha-9 genus; The three commonest HR were HPV-52, HPV-16, HPV-58, and the low-risk (LR) HPV were HPV-81, HPV-6, HPV-11; Single infection was absolutely predominant and the age group with the highest HPV detection rate was 26-30 years old. During 2014-2021, HPV-16, HPV-6 and HPV-11 decline, while HPV-58 and HPV-52 increased; Conclusions: The most prevalent age group of HPV in this region was 26-30 years old. The detection rate of HPV-52 increased in the region, overtaking HPV-16 as the commonest type of HPV. α-9 genus HPV with strong pathogenicity is the commonest HR HPV. HPV prevalence systematic comparison in certain areas and continuous time can accurately and intuitively understand its distribution changes, achieve analysis of the epidemic trend, and provide guidance for the prevention, treatment and scientific research of HPV in Sichuan.

[1]  Juan Zhao,et al.  Assessment of the effectiveness of HPV16/18 infection referred for colposcopy in cervical cancer screening in Northwest of China , 2017, Journal of medical virology.

[2]  Xianping Ding,et al.  L1 and L2 gene polymorphisms in HPV-58 and HPV-33: implications for vaccine design and diagnosis , 2016, Virology Journal.

[3]  Mengting Wang,et al.  Genetic variability in E6, E7, and L1 genes of human papillomavirus genotype 52 from Southwest China. , 2016, Gene.

[4]  Xianping Ding,et al.  Characteristics of HPV prevalence in Sichuan Province, China , 2015, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[5]  C. Mahidol,et al.  Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs , 2015, Infectious Agents and Cancer.

[6]  H. Warke,et al.  Variations in immunogenetics, human papillomavirus (HPV) infection & predisposition to cervical cancer in Indian women , 2014, The Indian journal of medical research.

[7]  J. Salmerón,et al.  The Peru Cervical Cancer Screening Study (PERCAPS): The Design and Implementation of a Mother/Daughter Screen, Treat, and Vaccinate Program in the Peruvian Jungle , 2014, Journal of Community Health.

[8]  J. Archambault,et al.  The E1 proteins. , 2013, Virology.

[9]  R. DeSalle,et al.  Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67 , 2011, PloS one.

[10]  F. Zhang,et al.  Human Papillomavirus Type 16 Variant Analysis of E6, E7, and L1 Genes and Long Control Region in Identification of Cervical Carcinomas in Patients in Northeast China , 2011, Journal of Clinical Microbiology.

[11]  Shulan Zhang,et al.  Characteristics of HPV prevalence among women in Liaoning province, China , 2010, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[12]  M. Wu,et al.  Human papillomavirus infection in Beijing, People's Republic of China: a population-based study , 2009, British Journal of Cancer.

[13]  Abdelatif Elouahabi,et al.  Cervarix™, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions , 2009, Human vaccines.

[14]  D. Weiner,et al.  Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. , 2008, Vaccine.

[15]  C. Nishida,et al.  Development of a WHO growth reference for school-aged children and adolescents. , 2007, Bulletin of the World Health Organization.

[16]  A. Giuliano,et al.  Prevalence of HPV infection among men: A systematic review of the literature. , 2006, The Journal of infectious diseases.

[17]  P. Coursaget,et al.  Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. , 2003, The Journal of infectious diseases.

[18]  R. Pötter,et al.  Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer , 2002, International journal of cancer.